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Adeno-associated virus (AAV) is the only known eukaryotic virus
capable of targeted integration in human cells. An AAV Rep
binding element (RBE) and terminal resolution site (trs) identical to
the viral terminal repeats required for AAV DNA replication are
located on chromosome (ch) 19. Both ch-19 RBE and trs elements
have been shown to be essential for viral targeting to this locus. To
characterize the role of the AAV inverted terminal repeat (ITR)
cis-acting sequences in targeted integration an AAV trs mutant
incapable of supporting viral replication was tested. Wild-type and
mutant substrates were assayed for targeted integration after
cotransfection in the presence or absence of Rep. Our results
demonstrated that, in the presence of Rep78, both ITR substrates
targeted to ch-19 with similar frequency. Molecular characteriza-
tion of the mutant ITR integrants confirmed the presence of the trs
mutation in the majority of samples tested. Complementation
analysis confirmed that the mutant targeted viral genomes were
unable to rescue and replicate. In addition, Rep78 induced exten-
sive rearrangement and amplification of ch-19 sequences indepen-
dent of wild-type or mutant targeting substrate. These studies
demonstrate that Rep-dependent nicking of the viral cis-acting trs
sequence is not a prerequisite for site-specific recombination and
suggests AAV targeting is mediated by Rep7868-dependent rep-
lication from the ch-19 origin of replication (ori). These studies have
significant impact toward the understanding of AAV site-specific
recombination and the development of targeting vectors.
Adeno-associated virus (AAV) has a biphasic life cycle. In thepresence of helper virus, Adenovirus (Ad), or Herpesvirus
(HSV), AAV undergoes a productive infection. Lacking a helper
virus, AAV latently infects by integration into the host genome.
AAV is the only known eukaryotic virus capable of undergoing
site-specific integration into the human genome (1). The ability to
integrate site specifically is one of the attractive features for
considering this virus as a vector for human gene therapy (2).
Wild-type (wt) viral DNA recombines at chromosome (ch)-
19.13.3 qter at a frequency of 70% (3), a reaction that depends
on the AAV replication (Rep) proteins (4, 5) Rep78 and Rep68
(6–8). Mutational analysis of Rep78 and Rep68 proteins indi-
cates that DNA binding, site-specific endonuclease activity, and
helicase activities are critical for site-specific recombination (1,
6, 9, 10).
The only viral cis elements necessary for targeted integration
are the 145-bp inverted terminal repeats (ITRs). The ITRs also
serve as the origins of replication (ori) for viral DNA synthesis
and are the essential cis components required for generating
AAV integrating vectors. In the absence of Rep, recombinant
AAV (rAAV) integrates randomly. Although the mechanism of
viral integration is unknown, wtAAV and rAAV proviral struc-
tures are similar because they are typically arranged in head to
tail concatamers, have micro sequence homology at junctions,
and possess variable ITR and chromosomal deletions (3, 11–14).
These observations led to the conclusion that both Rep-
dependent site-specific integration and random integration de-
pend on the cellular recombination machinery (14). The ch-19
integration site, unique to primates (15), contains a Rep-
responsive ori both in vitro (16) and in vivo (17). In the presence
of Rep the ch-19 region is amplified and rearranged indepen-
dently of site-specific recombination (17, 18). The ch-19 cis
sequences that direct Rep dependent replication share 86%
sequence identity to the AAV ITR (19–21). The ch-19 region
contains a Rep binding element (RBE) and a terminal resolution
site (trs) also found within the viral ITR (9, 19). Thirty-three base
pairs of ch-19 containing the RBE and trs is sufficient for
site-specific recombination (9, 20). Deletion of the trs resulted in
a loss of viral targeting (9, 20). Episomal integration depends on
both the sequence and position of the spacer DNA separating the
RBE and trs motifs (21). Furthermore, in the presence of Rep,
these ch-19 cis elements are sufficient to direct site-specific
recombination in rodent models independent of chromosomal
context (17, 22). Although these data support the role of critical
ch-19 cis elements in targeted integration, a similar analysis of
the required viral elements has not been performed.
The goal of this study is to determine whether AAV site-
specific recombination is coupled to Rep-dependent replication
by means of the AAV ITR ori. To test this, a modified viral ITR
that contains an 8-bp insertion between the AAV RBE and trs
(Fig. 1 A) was used. Rep-dependent resolution in an in vitro
nicking assay was over 100-fold less efficient when using this
substrate compared with wt sequences (23). Consistent with the
in vitro data, these modified ITRs were also deficient for AAV
viral production in vivo (X. Xiao and R.J.S., unpublished data).
Using transfection assays, the mutant ITR was tested for tar-
geted integration in the presence of AAV Rep78. Here we show
that mutant viral ITRs containing a nonfunctional trs exhibited
the same targeting frequency as those containing a wt ITR.
Furthermore, the ch-19 region was amplified and rearranged
regardless of the targeting substrate used. These data support the
conclusion that Rep-dependent replication of ch-19 and not the
viral ITR is required for site-specific recombination.
Materials and Methods
Maintenance of Cells. HeLa cells were grown in DMEM supple-
mented with 10% heat-inactivated FBS. Cells were grown at
37°C in a 5% CO2 humidified incubator.
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Plasmids and DNA. pwtITR-neo plasmid was constructed by di-
gesting psub201 (24) with SnaBI and ligating it to the 1-kb
AccI-XhoI fragment of MC Neo poly(A) (Stratagene). The
XhoI-AccI fragment was blunted and ligated to psub201 gener-
ating the following cassette, the TK promoter, neo resistance
gene, and a poly(A) signal sequence between the AAV ITRs (1.3
kb). pHpaITR-neo was constructed identically to pwtITR-neo
except that the pHpa8 plasmid (23) was used as the vector
backbone. The plasmids were maintained in SURE cells
(Stratagene).
Single Cell Cloning. To obtain clonal cell lines, cells were trans-
fected with neo-resistant plasmids plus and minus Rep con-
structs (28). After 48 h, cells were trypsinized and plated at
dilutions of 1:10, 1:50, and 1:100 under G418 selection (600
gml). After 8 days of selection, colonies were isolated and
propagated as described (15). All stable clones were maintained
in 300 gml G418.
AAV Replication Assay. Replication assays were carried out by
transfecting HeLa cells with pwtITR-neo or pHpaITR-neo, in
addition to XX6–80 (25) and Ad8 as described (25). Forty-eight
hours after transfection, Hirt extracts were performed (26) and
viral replication was characterized by sensitivity to Dpn I by
using Southern blotting analysis.
Southern Blot Analysis. Southern blotting analysis was carried out
as described (15). Briefly, ch-19 and neo sequence-specific
probes were generated by a Random Primer Labeling kit
(Boehringer). DNA was fractionated on agarose gels, trans-
ferred to filters, hybridized by using Quick-Hyb (Stratagene)
according to the manufacturer’s protocol, and finally exposed to
x-ray film for data analysis.
PCR Assay for Targeted Integration. Genomic DNA from clonal cell
lines transfected with the Rep expressing plasmid (pHIV78) and
pwtITRneo or pHpaITR-neo constructs was PCR amplified
following the protocol described by Samulski et al. (15), using a
modification described by Urabe et al. (10). Ten microliters of
the reaction was fractionated on a 1.2% agarose gel. Gels were
subjected to Southern analysis by using a ch-19 or neo-specific
probe. PCR analysis was carried out with single ch-19 primers to
rule out any potential false positives. Controls included single
primer reactions of ch-19 and Neo vector, respectively. Only
positive PCR products obtained from reactions containing both
primers [ch-19 primer 2649 and AAV A stem primer (15)] were
identified as ch-19 targeted integration.
Results
HpaI ITR Constructs Are Defective for Rep-Dependent Replication.
Three components are currently known to be required for AAV
targeted integration: Rep proteins in trans, cis-acting AAV ITR
and ch-19-specific sequences. Of the ch-19 cis-acting sequences,
the RBE, trs, and the spacer element between these motifs are
essential for site-specific recombination (20, 21). An understand-
ing of the specific AAV cis-acting ITR sequences required,
specifically the role of the trs, has not been established. Moving
the viral trs 8 bp downstream of its normal position (Fig. 1A)
results in a 100-fold reduction in Rep-mediated nicking in an in
vitro assay (23). By using Hirt analysis (27) to assay the ITR
mutant for AAV replication in vivo, these in vitro observations
were extended. After transfection into permissive HeLa cells,
replicated AAV DNA was assessed by sensitivity to DpnI
digestion. In the absence of Dpn I treatment, both wt and mutant
input plasmids were detected (Fig. 1B, lanes 1 and 3). However,
in the presence of Dpn I, only the wt ITR plasmid substrate
yielded characteristic AAV monomer and dimer replication
intermediates (Fig. 1B, lane 2). These results corroborate our
previous in vitro studies and confirm the mutant ITR as a
replication negative substrate in vivo despite the presence of Rep
(Fig. 1B, lane 4).
Role of Viral trs in ch-19 Site-Specific Recombination. Experiments
have shown that AAV ITR-containing plasmids target ch-19 when
either Rep78 or Rep68 is supplied in trans (6–8). To determine the
requirement of a functional AAV ITR ori in site-specific recom-
bination, neo-resistant plasmids containing the altered AAV
replication-defective ITR (pHpaITR-neo) or wt ITR (pwtITR-
neo) were transfected into HeLa cells with and without Rep-
expressing constructs and single-cell clones were selected in G418
(6, 28). The frequency of neo-resistant colonies reflects the inte-
gration frequency. Both wt and mutant plasmids showed Rep-
dependent increases in the integration frequencies, with 4.5- and
3-fold increases, respectively (Table 1). In the presence of Rep, only
a 1.8-fold increase in the number of resistant colonies with the wt
ITR compared with the mutant was seen (Table 1). In contrast to
the dramatic inhibition of AAV replication by the mutant ITR, its
effect on integration frequency appeared minimal.
To determine whether mutant ITR genomes inserted site-
specifically into ch-19 sequences, random neo-resistant clones
were selected and genomic DNA was analyzed by Southern
blotting. DNA was digested with ApaI, an enzyme that does not
cut the AAV ITR plasmids but releases a 2.8-kb ch-19 genomic
fragment that contains the majority of AAV site-specific recom-
binants (7, 14, 15, 29). When using a ch-19 sequence specific
Fig. 1. AAV replication assay of wt and mutant ITR neo vectors. AAV ITR in
hairpin configuration. RBE and trs are boxed and labeled. The 8-bp HpaI linker
insertion CCAATTGG and position of insertion is illustrated. The details for
construction have been described (23). (B) Southern blot analysis of wt and
pHpaITR vector substrate for replication. Hirt analysis of low molecular weight
DNA after cotransfection with Ad helper plasmid XX-6–80, pAB11, and either
the pwtITR-neo (wt) or pHpa-ITR neo (Hpa) construct was carried out as
described in Materials and Methods. The positions of input AAV plasmids
(lanes 1 and 3) and Dpn I-resistant (lanes 2 and 4) replicative forms are shown.
The 1.3- and 2.6-kb Dpn I-resistant replicative forms are denoted by m (mono-
mer) and d (dimer) and molecular weight markers are shown.






(A) pwtITR-neo and pHpaITR-neo constructs were transfected into HeLa
cells with (Rep78) and with out (no Rep78) Rep78 expression plasmids.
Experiments were done in triplicate and random colonies were selected and
expanded in G418 for genomic analysis.
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probe, in the absence of Rep, only the expected 2.8-kb genomic
band was observed (Fig. 2A). When either wt or mutant ITR
plasmids were introduced in the presence of Rep, we detected
amplification and rearrangement of the ch-19 target sequence in
84% pwtITR-neo clones and 69% pHpaITR-neo colonies (Table
2, Fig. 2B). Hybridization with a neo-sequence-specific probe
(Fig. 2C) showed that 32% pwtITR-neo clones were targeted to
ch-19 based on the comigration of ch-19 and neo-specific
sequences (Table 2) and is in agreement with previous reports,
using AAV plasmids for ch-19 targeting (6–8). In the case of
pHpaITR-neo, 47% were targeted (Fig. 2C, Table 2). In the
absence of Rep78, no ch-19 rearrangement or targeting with
either ITR vector substrate was observed (Fig. 2 A, Table 2).
Expression of Rep in the absence of AAV vector is sufficient to
rearrange and amplify the ch-19 sequence (17). To rule out the
possibility that unlinked neo-positive and rearranged ch-19 frag-
ments comigrated in these experiments, genomic DNA was ana-
lyzed for the linkage of vector and ch-19 sequences by PCR. The
primer pair consisted of a ch-19-specific and an AAV-vector-
specific primer (10, 14, 15). PCR products were analyzed by
Southern blotting, using both ch-19-specific and vector-specific
probes (data not shown). The results confirmed those obtained by
genomic Southern analysis; in the absence of Rep no clones (012)
from either pwtITR-neo or pHpaITR-neo colonies scored positive
for vectorch-19 junctions (Tables 2 and 3). However, 53%
pHpaITR-neo clones were positive for targeted integration in the
presence of Rep78 (Table 3). Two clones (H#15 and H#16) were
positive for site-specific integration by PCR, but negative by
genomic Southern. One clone (H#1) was positive by Southern but
negative when using this set of PCR primers (Table 3). In total, 11
pHpaITR-neo  Rep78 clones could be classified as targeted
(58%), with 8 of 11 clones (42%) positive by both assays. For
comparison, 32% of clones established by the wt ITR substrate were
identified as targeted. Based on these observations, the mutant ITR
showed no defect in AAV site-specific integration, indicating that
a functional AAV ITR ori as defined by in vitro nicking and in vivo
replication is not required for this process.
Mutant ITRs Remain Intact After Integration. The AAV ITR is highly
recombinogenic and will gene convert very efficiently (27, 30).
If efficient gene conversion of mutant to wt ITR sequences
occurred before integration, it would appear as if mutant AAV
ITR vectors could undergo efficient targeting. To ensure that
ch-19 targeted pHpaITR-neo clones had not gene converted to
a functional AAV ITR ori before integration, the status of
integrated vector was determined by Southern analysis.
Fig. 2. Southern analysis of wt and pHpaITR neo-resistant genomic DNA.
Creation of neo-resistant clonal cell lines and analysis was carried out as
described in Materials and Methods. ApaI-digested genomic DNA releases a
2.8-kb fragment of the ch-19 preintegration region, but does not cut the
vectors. ApaI digestion of HeLa cell genomic DNA before transfection assays
was used as control (lane C) in all experiments (A–C). Molecular weight
markers are indicated on the left of the gel. (A) ApaI-digested genomic DNA
from wt (lanes 1–6) and mutant ITR (lanes 7–12) neo-resistant clones minus
Rep78. DNAs were analyzed by using a ch-19-specific probe (see Materials and
Methods for details). Presence of a 2.8-kb genomic signal is indicative of lack
of site-specific integration (lanes C and 1–12). (B) ApaI-digested genomic DNA
from randomly selected wt (lanes 1–9) and mutant ITR vector (lanes 10–19)
neo-resistant clones cotransfected with Rep78-expressing plasmid pHIV78
(see Materials and Methods for details). Amplification and rearrangement of
ch-19-specific region is indicated by multiple bands (lanes 1–19) compared
with control (C). (C). Analysis of B by using a neo-specific probe after stripping
of ch-19-specific sequences. Absence of the major 2.8-kb ch-19 signal and lack
of neo-specific signal in the control lane (C) indicate specificity of the neo
probe for vector sequences. Site-specific recombination was assigned to clones
that contained bands that cohybridized both to the neo probe (arrowheads in
C) and the ch-19 probe (arrowheads in B) as described (42).
Table 2. Analysis of integration status of wtITR of HpaITR clones
Clones #R %R #T %T
pwtITR-neo Rep78 1619 84 619 32
pHpaITR-neo Rep78 1319 69 919 47
PwtITR-neoRep78 06 0 06 0
PHpaITR-neoRep78 06 0 06 0
Genomic DNA from 19 wild-type or 19 mutant ITR neo-resistant clones
cotransfected with pHIV Rep78-expressing plasmid (Rep78) were scored for
ch-19 rearrangement after ApaI digestion (see Fig. 2 for illustration). The
number rearranged (#R) and percent rearranged (%R) ch-19 sequences are
indicated. Cohybridization to both ch-19 and vector-specific probe (as illus-
trated in Fig. 2 B and C) was used to determine the number targeted (#T) and
percent targeted (%T). Similar analysis of wt and mutant ITR constructs in the
absence of Rep expression (pwtITR-neoNo Rep78, pHpaITR-neoNo Rep78)
served as controls.
Table 3. Analysis of pHpaITR genomic clones
Clone Southern PCR No. of HpaI sites Rescue
H#1   2 ND
H#2   1 
H#3   2 
H#4   ND ND
H#5   ND 
H#6   ND 
H#7   0 
H#8   1 
H#9   ND 
H#10   ND ND
H#11   ND ND
H#12   2 ND
H#13   ND ND
H#14   ND ND
H#15   2 ND
H#16   2 
H#17   2 
H#18   2 
H#19   ND ND
Detailed characterization of 19 pHpaITR genomic isolates for ch-19 target-
ing. Results from Southern (Southern blot analysis), PCR (PCR analysis), pres-
ence of mutated ITR after integration (# of HpaI Sites), and ability to re-enter
the AAV lytic cycle (Rescue) after superinfection with helper viruses are
described. Results are listed as clone number (Clone #, 1–19); , positive; ,
negative; ND, not done; and 0, 1, or 2, the number of HpaI sites present after
Southern analysis using HpaI digestion.








pHpaITR-neo clonal genomic DNA was digested with HpaI and
analyzed by using a neo-specific probe. The appearance of a
1.3-kb fragment is indicative of an integrated mutant vector
containing a HpaI site within each ITR. The majority of the
clones (67%) retained both HpaI sites. Two clones (22%) lost
one HpaI site, and 1 clone (11%) lost both HpaI sites (Table 3).
This analysis dismissed the possibility that pHpaITR-neo had
gene converted to a functional AAV ITR ori before integration.
AAV Rescue Assay. A hallmark of the AAV life cycle is the ability
of the proviral genome to rescue from the latent state and
reenter the lytic life cycle when super infected with helper virus.
Rescue occurs 50–60% of the time in latently infected cell lines
(3). This aspect of AAV integration takes place with wtAAV or
rAAV (14). Because the mutant ITR substrates were defective
for AAV replication (Fig. 1B), but competent for efficient
targeted integration (Fig. 2, Table 2), we assayed stable clones
for rescue after infection with helper virus. Unlike wt ITR cell
lines, all clones tested that retained two mutant ITRs were
defective for rescue (Table 3). The inability to rescue is consis-
tent with the mutant ITR as a nonfunctional template for
replication. These data suggest that a functional ITR, as defined
by AAV lytic replication, is not required for targeted integration.
However, one clone that contained one defective ITR demon-
strated a weak signal for rescue product. Differential hybridiza-
tion with AAV and ch-19 probes demonstrated that the majority
of the signal was for ch-19 sequences (data not shown). This
rescue molecule appears to be an interesting variant of AAV
linked to ch-19 sequences. Further studies are ongoing to
determine the molecular configuration of this chimeric substrate
and whether the ch-19 ori serves as the template for rescue.
Discussion
In this study, the role of an AAV mutant ITR for the ability to
target ch-19 was evaluated. Although this mutant is defective for
AAV Rep-dependent replication (Fig. 1), our results demon-
strate that the modified terminal repeat sequence is completely
competent for ch-19 site-specific integration (Fig. 2, Tables 1–3).
Both the efficiency and frequency of targeting was equal to or
better than wt substrates (Table 2). These studies are of signif-
icant importance because they begin to define the role of the
viral cis sequences required for site-specific integration.
Currently, AAV targeted integration requires three known
components: Rep proteins in trans, cis-acting ch-19-specific
sequences, and the AAV ITR elements. Of the ch-19 cis-acting
sequences, the RBE and trs element are essential for site-specific
recombination (20). Recently, a third component of ch-19, the
spacer element between these motifs, was shown to be critical for
site-specific recombination and by increasing the distance be-
tween the ch-19 RBE and trs completely abolished targeted
integration (21). Similar to these studies, an 8-bp increase in the
spacer region between the AAV ITR RBE and trs resulted in a
100-fold decrease in Rep-dependent nicking in vitro (23) and
complete absence of viral replication in vivo (Fig. 1B). Contrary
to the loss of integration specificity observed with modified ch-19
spacer sequence substrates, the modified AAV ITR targeted
ch-19 at a similar frequency to the wtITR (Fig. 2, Table 2). Also,
the mutant ITR was retained after integration, ruling out the
possibility of gene conversion to a wt ITR before targeting
(Table 3). All clones assayed were negative for rescue when
challenged with helper virus, with one exception (Table 3).
These data suggests that Rep-dependent nicking of the AAV
ITR as defined by in vitro assays and in vivo AAV replication
assays is not required for site-specific integration.
The Role of Rep-Dependent Replication in Targeting. Loss of the trs
in the ch-19 region results in a loss of targeting capability (9, 20)
and suggests that the ability of Rep78 and Rep68 to initiate
replication on ch-19 is essential to the integration reaction. This
hypothesis is supported by Rep68’s ability to initiate replication
on ch-19 in vitro (16), and the fact that the majority of break-
points identified in vivo are located downstream of the ch-19 trs
(15). Furthermore, we demonstrated in vivo amplification and
rearrangement of ch-19 in the presence of Rep78 when no
targeting vector substrates were present (17).
What Is Unique About the ch-19 Site? In addition to carrying the
cis-acting RBE and trs, the ch-19 target locus contains DNA
elements that promote an open chromatin conformation (31).
This DNA conformation may be essential for initiating Rep
interaction with the ch-19 target locus. In support of this
concept, the ch-19 cis elements have been able to direct site-
specific recombination to non-ch-19 regions in animal models
(17, 22). These models share 1.6 kb of ch-19 in common,
additional experiments are required to determine whether the
minimal cis elements (33 bp) identified in the EBV episomal
integration assay system are sufficient for in vivo targeting. At
present, these 33 bp do not include the DNase hypersensitive
site.
Initial Steps in AAV Targeting. All of these data and numerous
biochemical studies in vitro support a model for site-specific
integration (Fig. 3) where Rep initiates replication on ch-19 (Fig.
3A) by interaction with the ch-19 RBE and trs. Most likely
asymmetric replication on the ch-19 ori (16) begins by Rep
unwinding the ch-19 RBE creating a replication bubble followed
by site- and strand-specific nick at the ch-19 trs. Rep7868
becomes covalently attached to the 5 end of the cut site by
means of tyrosine phosphate linkage (Fig. 3B; ref. 32) and
generates a free 3-OH substrate that can be used to initiate
replication (33, 34). As replication proceeds, the 5 strand gets
displaced and generates a flap (Fig. 3B; ref. 1). The 5 f laps that
are generated during cellular replication are typically removed
by the FEN-1 protein (35). However, FEN-1 protein only acts on
single-stranded DNA substrates, and are blocked by flaps with
double-stranded ends (36) or single-stranded flaps protected by
5 protein (37, 38). In the absence of RAD27, yeast homologue
of FEN-1, there is an increased rate of recombination, duplica-
tions, and double-stranded breaks in the host genome (39). In
addition, trinucleotide repeat disease appears to be related to
inability of FEN-1 enzyme to resolve flaps containing CAG
repeats because of hairpin conformation (36), and results in
large expansion of these sequences. It is possible that unsched-
uled DNA replication mediated at ch-19 by Rep would generate
substrates (protein-linked 5 f laps) that become recombination
‘‘hot spots’’ (Fig. 3B). Because Rep7868 will be covalently
attached to the displaced strand, it is likely that it will inhibit the
ability of FEN-1 to process the displaced strand. The inability to
process this displaced strand would lead to amplification and
rearrangement of the chromosomal region (38). We recently
documented amplification and rearrangement of ch-19 in the
presence of Rep alone (17). These data suggest that Rep-
mediated replication of ch-19 is sufficient to generate all chro-
mosomal recombination products observed after site-specific
integration and the extent of amplification and rearrangement of
the ch-19 integration region may be subject to repeated Rep
initiation on the ch-19 ori (Fig. 3C). Evidence supporting this
idea comes from experiments using a hormone-regulated Rep68
construct that expressed Rep68 transiently at lower levels re-
sulted in a decrease in the amount of amplification and rear-
rangement of the ch-19 region (18). We previously demonstrated
that Rep78 and Rep68 are present at 1,000–4,000 copies per
latently infected HeLa cell although this may vary from cell type
to cell type. This amount of Rep may increase the rate of
initiation and lead to an accumulation of Rep-covalently linked
5 f laps (Fig. 3C) and ultimately lead to an increase of rear-
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rangement and amplification through the cell’s inability to
process these replication by-products. It is of interest to note that
a minute virus of mice (MVM)-based targeted recombination
system reported that the amplification and rearrangement of the
target DNA region was similar to ch-19 region (40). Both
reactions are dependent on their respective large nonstructural
proteins and are similar in function and enzymatic activity (1).
The similarities of the enzymatic activities of the large nonstruc-
tural proteins points to a common mechanism of amplification
and rearrangement that may be a result of their respective
enzymatic nature (i.e., covalent attachment after site-specific
endonuclease activity; Fig. 3B). Whether reinitiation is required
or not for more efficient targeting, our data supports site-specific
integration at ch-19 in the absence of classical Rep-mediated
nicking of the viral ITR substrate. Our data supports a concept
first proposed by Owens and colleagues (19) where Rep facili-
tates site-specific integration by mediating complex formation
between the viral ITR and the ch-19 locus (Fig. 3D). Because
targeted integration depends on the trs being located in the
correct proximity to the RBE on ch-19 but not on the viral
ITR implies that the incoming substrate may only require
Rep-binding activity. Further studies in vivo with additional
ITR mutant substrates should help define the minimal require-
ments of the terminal repeat sequences for AAV site-specific
integration.
ch-19 Amplification and Rearrangement. The enzymatic steps re-
quired after complex formation to establish stable ch-19 inte-
grants have been previously alluded to (Fig. 3E; refs. 9, 17, 20,
and 41). Proviral structures for AAV vectors devoid of Rep
result in identical head-to-tail concatamers and region-specific
deletions in the terminal repeats as well as microhomology at the
viralcellular junctions are also observed, albeit at random sites
in the genome (12, 14, 42). The mutant ITR proviral genomes in
this study were predominantly head-to-tail concatamers that also
contained the plasmid backbone (data not shown; ref. 43). The
formation of head-to-tail concatamers may be a general by-
product of eukaryotic cells and not specifically related to AAV
substrates. For example, episomal forms of AAV vectors readily
form head-to-tail concatamers in the absence of Rep, a feature
now being exploited to overcome AAV packaging limitations
(44, 45). Head-to-tail concatamers is a distinguishing feature of
all transgenes when generating transgenic animals and config-
uration of other DNA virus (SV40, Ad, etc.) proviral structures
(46, 47), and was first described by Schimke and colleagues after
transfection of naked DNA into eukaryotic cells (48–50). From
this perspective, AAV carries many hallmarks of illegitimate
recombination; deletions and duplications at the insertion sites,
head-to-tail concatamers, and amplification and rearrangement
of the integration locus. These proviral structural similarities
between wt, mutant ITRs, and AAV vectors suggest a similar
mechanism of concatamer formation and DNA amplification
carried out by cellular factors (Fig. 3E). These observations help
to define Rep’s role in site-specific recombination, which ap-
pears to be to initiate unscheduled ch-19 replication and facil-
itate the interaction of viral and ch-19 sequences by Rep–Rep
protein interaction.
Implications for Gene Therapy and Targeting Vectors. A key feature
of the wt AAV biphasic life cycle and an aspect associated with
current AAV vectors is the ability of the provirus to reenter the
lytic pathway when all necessary helper functions are present.
Our data showed that the modified ITR was capable of site-
specific integration of plasmid substrates but deficient for rescue
and replication when challenged with permissive conditions. The
inability to rescue would eliminate the risk of vector dissemina-
tion after incidental superinfection with wt AAV and helper
virus, a feature now associated with current AAV vectors. AAV
plasmid vectors carrying the modified ITRs could exploit this
aspect of targeted integration without the risk of rescue. Because
a functional AAV ITR ori is not required for ch-19 targeting, we
view the mutant ITR substrate as a second-generation AAV
plasmid vector that has site-specific recombination-only activity.
Characterization of additional mutations in the AAV ITR may
result in more efficient targeting vectors (i.e., expanded RBE
elements, modified hairpins, etc.). In addition, the mutant ITRs
Fig. 3. AAV integration model. (A) Complex of Rep proteins (yellow circles labeled Rep) initiate unscheduled replication on ch-19 by interaction with the ch-19
RBE and trs. (B) Asymmetric replication on the ch-19 origin ensues by Rep unwinding the ch-19 RBE creating a replication bubble followed by site- and
strand-specific nick at the ch-19 trs. Rep7868 becomes covalently attached to the 5 end of the cut site by means of tyrosine phosphate linkage and generates
a free 3-OH substrate that can be used to initiate replication (dashed blue line). As replication machinery proceeds (blue circle labeled pol), the 5 strand gets
displaced and generates a flap (Rep yellow circle attached to solid line). The DNA replication mediated at ch-19 by Rep would generate substrates (protein-linked
5 flaps) that become recombination ‘‘hot spots’’ (see Discussion). (C) The extent of amplification and rearrangement of the ch-19 integration region may also
be subject to repeated Rep reinitiation on the ch-19 origin. This would result in multiple 5 flaps with covalently attached Rep proteins (yellow circles attached
to dashed lines) that influence the extent of amplification and rearrangement seen with site-specific recombination. (D) Complex formation between actively
replicating ch-19 sequences and Rep protein bound to AAV ITR sequences (hairpin structure). The dashed line representing the top strand of the AAV genome
indicates that either single- or double-stranded templates may be substrates for Rep complex formation carrying duplex ITRs. (E) Resolution of the viral genome
into the ch-19 locus is carried out by host enzymes that result in amplified (large green boxes) and rearranged (small green boxes) ch-19 sequences as well as
the characteristic AAV head to tail (light blue boxes labeled AAV genome) concatamers.








may remove other unwanted features of the viral ITR. For
example, the ITR has low-level basal transcription activity (51)
that has impeded the development of highly regulated AAV
expression vectors (52, 53). Based on the results of this study and
the recent characterization of these transcriptional elements
(51), it may be possible to generate variants vector substrates
containing additional mutations that are highly efficient for
integration (53). At minimum, the relevant cis elements (RBE,
ITR hairpin, etc.) required for efficient targeting should be
forthcoming from such studies. The mutant ITR integrating
plasmid vector described in this study may be important in
complementing efficient plasmid delivery systems currently
compromised by transient transduction (54). Finally, in vitro
integration systems aimed at defining the molecular steps re-
quired for AAV site-specific recombination are being developed
(14, 55). The data established in this study point to important
viral ITR cis-acting sequences required for targeting (i.e., RBE).
Further mutational analysis of the viral ITR aimed at defining
the role of the RBE element as described above should greatly
facilitate development of AAV site-specific in vitro integration
systems.
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